Arrowhead’s RNA drug, injected under the skin, appears to reach the brain and lower Alzheimer’s-linked tau protein in an early study.
endpoints.newsArrowhead’s brain-targeting drug lowers Alzheimer’s tau protein in early studyArrowhead Pharmaceuticals' ARO-MAPT subcutaneous injection reduced tau protein by up to 85% in healthy volunteers, potentially advancing Alzheimer's treatment without spinal injection.
1 repost3 likes